Strs Ohio Sells 33,555 Shares of Qiagen N.V. $QGEN

Strs Ohio decreased its holdings in Qiagen N.V. (NYSE:QGEN) by 86.8% in the third quarter, Holdings Channel.com reports. The institutional investor owned 5,096 shares of the company’s stock after selling 33,555 shares during the period. Strs Ohio’s holdings in Qiagen were worth $228,000 as of its most recent filing with the SEC.

Other institutional investors have also recently made changes to their positions in the company. Amalgamated Bank grew its stake in shares of Qiagen by 1.8% in the second quarter. Amalgamated Bank now owns 11,751 shares of the company’s stock worth $565,000 after acquiring an additional 209 shares during the period. Atria Investments Inc boosted its holdings in Qiagen by 2.9% in the second quarter. Atria Investments Inc now owns 7,674 shares of the company’s stock worth $369,000 after purchasing an additional 218 shares during the last quarter. ANTIPODES PARTNERS Ltd grew its position in Qiagen by 9.4% in the 2nd quarter. ANTIPODES PARTNERS Ltd now owns 2,566 shares of the company’s stock worth $123,000 after purchasing an additional 221 shares during the period. Yousif Capital Management LLC raised its stake in Qiagen by 3.7% during the 2nd quarter. Yousif Capital Management LLC now owns 6,257 shares of the company’s stock valued at $301,000 after buying an additional 222 shares during the last quarter. Finally, Covestor Ltd raised its stake in Qiagen by 13.6% during the 3rd quarter. Covestor Ltd now owns 3,007 shares of the company’s stock valued at $134,000 after buying an additional 361 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company’s stock.

Qiagen Stock Performance

Shares of QGEN opened at $52.20 on Tuesday. The business has a 50-day simple moving average of $49.58 and a two-hundred day simple moving average of $49.64. The company has a quick ratio of 2.30, a current ratio of 2.60 and a debt-to-equity ratio of 0.45. Qiagen N.V. has a 52 week low of $39.61 and a 52 week high of $57.81. The stock has a market cap of $11.02 billion, a price-to-earnings ratio of 26.95, a PEG ratio of 2.56 and a beta of 0.67.

Qiagen (NYSE:QGEN) last posted its quarterly earnings data on Thursday, November 6th. The company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.03. The firm had revenue of $532.58 million for the quarter, compared to analysts’ expectations of $525.68 million. Qiagen had a return on equity of 14.80% and a net margin of 19.58%.The business’s quarterly revenue was up 6.2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.60 EPS. On average, analysts expect that Qiagen N.V. will post 2.26 EPS for the current year.

Analyst Ratings Changes

QGEN has been the topic of a number of research reports. Citigroup downgraded Qiagen from a “buy” rating to a “neutral” rating and dropped their price target for the stock from $57.89 to $52.63 in a research note on Thursday, December 11th. UBS Group reissued a “neutral” rating on shares of Qiagen in a research report on Wednesday, January 21st. Weiss Ratings restated a “hold (c)” rating on shares of Qiagen in a research note on Monday, December 29th. Wall Street Zen cut shares of Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, January 10th. Finally, Barclays reissued an “overweight” rating and issued a $57.89 price objective (up previously from $55.79) on shares of Qiagen in a report on Monday, December 15th. Two research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $53.04.

Qiagen Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.